Assma Ben Aïssa
A5038825757- Cancer Immunotherapy and Biomarkers
- Glioma Diagnosis and Treatment
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Melanoma and MAPK Pathways
- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Single-cell and spatial transcriptomics
- vaccines and immunoinformatics approaches
- Cervical Cancer and HPV Research
- Monoclonal and Polyclonal Antibodies Research
- Ferroptosis and cancer prognosis
- Pituitary Gland Disorders and Treatments
- Neuroblastoma Research and Treatments
- Immune Cell Function and Interaction
- Bone health and treatments
- Ocular Oncology and Treatments
- Advanced Biosensing Techniques and Applications
- Angiogenesis and VEGF in Cancer
- Infectious Diseases and Mycology
- Drug-Induced Ocular Toxicity
- Neonatal Respiratory Health Research
University Hospital of Geneva
2012-2024
London Cancer
2016-2024
University College London
2016-2024
CRUK Lung Cancer Centre of Excellence
2017-2024
Hôpital Beau-Séjour
2023
Cancer Research UK
2019-2020
University of Geneva
2014
American Society of Safety Professionals
2012
Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune evasion. However, polymorphic nature locus has precluded accurate HLA copy-number analysis. Here, we heterozygosity in (LOHHLA), computational tool determine allele-specific copy number from sequencing data. Using LOHHLA, find that LOH occurs 40% non-small-cell lung cancers (NSCLCs) and associated with high subclonal neoantigen burden,...
Highlights•Anti-CTLA-4 of hIgG1 and hIgG2 isotypes promote depletion intra-tumoral Treg cells•hIgG2 antibodies mediate in vivo cells via CD32a•Anti-CTLA-4 with enhanced Fc effector function improves therapeutic outcomes•The CD16-V158F SNP is associated response to ipilimumab inflamed tumorsSummaryWith the use a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that equivalent tremelimumab regulatory T (Treg) cell vivo, increasing CD8+ ratio promoting tumor rejection....
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We demonstrated that expression largely restricted to tumor-infiltrating Treg in mice humans. While existing were observed deplete the periphery, upregulation of inhibitory Fc gamma receptor (FcγR) IIb tumor site prevented intra-tumoral cell depletion, which may underlie lack...
Patient-derived xenograft (PDX) models are widely used in cancer research. To investigate the genomic fidelity of non-small cell lung PDX models, we established 48 from 22 patients enrolled TRACERx study. Multi-region tumor sampling increased successful engraftment and most were histologically similar to their parent tumor. Whole-exome sequencing enabled comparison tumors provide an adapted mouse reference genome for improved removal NOD scid gamma (NSG) mouse-derived reads data. model...
Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as potent radiosensitizer by arresting cells in the most radiosensitive cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine safety maximum tolerated (MTD) of Sb combination with radiation therapy (RT) temozolomide (TMZ) 17 patients newly diagnosed high-grade glioma. Patients were treated RT (60 Gy 2 fractions) combined...
Despite the advances in cancer immunotherapy, only a fraction of patients with bladder exhibit responses to checkpoint blockade, highlighting need better understand drug resistance and identify rational immunotherapy combinations. However, accessibility tumor prior during therapy is major limitation understanding immune microenvironment (TME). Herein, we identified urine-derived lymphocytes (UDLs) as readily accessible source T cells 32 muscle invasive (MIBC). We observed that effector CD8+...
Pre-clinical non-small cell lung cancer (NSCLC) models are poorly representative of the considerable inter- and intra-tumor heterogeneity disease in patients. Primary cell-based vitro NSCLC therefore desirable for novel therapy development personalized medicine. Methods have been described to generate rapidly proliferating epithelial cultures from multiple human epithelia using 3T3-J2 feeder culture presence Y-27632, a RHO-associated protein kinase (ROCK) inhibitor, what known as...
ABSTRACT Patient-derived xenograft (PDX) models of cancer, developed through injection patient tumour cells into immunocompromised mice, have been widely adopted in preclinical studies, as well precision oncology approaches. However, the extent to which PDX represent underlying genetic diversity a patient’s and on-going genomic evolution are incompletely understood, particularly context heterogeneous cancers such non-small cell lung cancer (NSCLC). To investigate depiction intratumour...
Introduction Significant therapeutic changes have recently occurred in the management of melanoma brain metastases (BMs), both field local treatments, with rise stereotactic radiotherapy (RT), as well systemic ones, advent immunotherapy and targeted therapies (TT). These advances brought about new challenges, particularly regarding potential interactions between TT (notably BRAF/MEK inhibitors) irradiation. Through a clinical case, we will discuss side effect not previously described...
Melanoma is the most aggressive skin cancer, and surgery standard of care for localised disease. However, a risk local distant relapse exists despite tumour removal, particularly with thick or ulcerated tumours lymph node involvement. Immunotherapy immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L-1 CTLA-4 demonstrated improved relapse-free survival metastasis-free against placebo after stage-III high-risk stage-II melanoma. In unresectable metastatic tumours, double immunotherapy...
Amoebiasis is the third leading cause of mortality due to parasitic infection worldwide after malaria and schistosomiasis. The direct pulmonary Entamoeba histolytica rarer than reactive events called “neighborhood”. We report role imaging in diagnostic orientation a case amoebic pleuropulmonary damage (associated with serology parasitology). Before an excavated lesion, can be great contribution working diagnosis parasite histolytica.
Abstract. Immunotherapy with immune checkpoint inhibitors (ICI) is administered in different cancer types and can lead to a wide range of immune-related adverse events including toxicity vital organs such as the lungs, kidneys, heart. The main hypothesis suggests an overactivation cells organs. Whereas cardiotoxicity very rare but life threatening, ICI-induced acute kidney injury pneumonitis are more frequent general less severe. Renal corresponds than 90% tubulo-interstitial nephritis....
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Objectives:To identify new magnetic resonance imaging (MRI) patterns in patients with high-grade glioma treated bevacizumab (Avastin®). Methods:The retrospective study was approved by the institutional review board. An extended case series of 27 (19 men, 8 women) age range 22–76 years and an average 52 were studied 1.5T/3T MRI (Siemens scanner Erlangen, Germany). Protocol included axial T1-wi spin echo (SE), T2-wi fast SE, three-dimensional fluid-attenuated inversion recovery (3D FLAIR),...
12009 Background: The lung TRACERx study is a prospective exploring the cancer genome evolution of NSCLC. Data analysis from first 100 patients enrolled into has shown an increased risk recurrence or death associated with intratumoural genomic heterogeneity. importance phylogenetic clonality neoantigens in predicting overall survival NSCLC and response to checkpoint blockade previously reported. Methods: We hypothesised that mutational burden heterogeneity reflected intra-tumoural T cell...
TPS9599 Background: Several large-scale clinical trials of pembrolizumab have demonstrated substantial efficacy and survival benefit in metastatic melanoma (MM). However, responses are limited to a fraction patients (pts), highlighting the need decipher mechanisms that drive resistance identify biomarkers predictive response, thus guide rational development new combinations immunomodulatory drugs. ADAPTeM will compare paired intratumoral peripheral immune responders non-responders following...